This expanded renewal application will support training in immunology and support three pre-doctoral, two post-doctoral PhD and two post-doctoral MD trainees at Baylor College of Medicine and affiliated institutions.
The specific aims of this application are 1) to recruit promising young scientists with a passion for immunology research;2) to increase access to high quality research mentors 3) to increase the desirability of a research career for physicians;and 4) to increase access to developmental mentoring functions including career development. Training is performed at two institutions, Baylor College of Medicine and the MD Anderson Cancer Center (MDACC) in Houston, Texas, with all training faculty engaged in inflammatory disease and immunology research. Since the last submission of this application, Baylor College of Medicine has undergone several substantial changes, including merging of the former Departments of Immunology and Pathology, creating a single Department of Pathology &Immunology;launching the building of its first wholly-owned medical care facility;recruiting to Baylor and Texas Children's Hospital of Drs. Peter Hotez, director of the first National School of Tropical Medicine in the United States, and Jordan Orange as Chief of Pediatric Immunology, Allergy, and Rheumatology. In response to these changes, the two prior immunology-related T32 training grants at Baylor have been merged, forming this single renewal application. David B. Corry, M.D., will direct the merged T32 and will be assisted by an external advisory board and an internal steering committee, all comprised of immunologists having MD and/or PhD backgrounds. Trainees accepted into the program will be chosen from pre-doctoral applicants primarily from the Graduate Program in Immunology and PhD and MD postdoctoral applicants from the laboratories of the program faculty. Post-doctoral fellows will also be recruited nationally. Pre-doctoral applicants will be appointed in their first year, after hey have passed their qualifying exams. Required coursework will include training in the ethical conduct of science and trainees must attend weekly journal clubs, weekly seminars given by invited speakers and will be required to present their research at a campus-wide immunology seminar. All trainees will receive guidance on how to build careers in science, regardless of their backgrounds and will be expected to attend international scientific symposia. Research advisory committees will be assembled for each trainee, which will meet at least twice per year to provide research and career guidance. Baylor and the Texas Medical Center offer an exceptional scientific training environment. This program has and will continue to strive to attract premier immunology trainees, including underrepresented minority (URM) and female applicants. The Graduate School has established itself as a national leader in recruiting and finishing URM pre-doctoral students, with approximately 20% URM students, partly through exemplary support programs. As such, this training program will continue to produce premier MD and PhD immunologists for careers in science.

Public Health Relevance

Immune or inflammatory mechanisms underlie the vast majority of human diseases. Modern immunology offers the opportunity to make substantial additional improvements in human health through improved vaccines, immunosuppressive strategies, and improved methods to combat cancer. Participants in this immunology training program will receive guidance in these important areas and emerge as effective scientists who will study immune mechanisms of human disease and help to advance human health.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Institutional National Research Service Award (T32)
Project #
2T32AI053831-11A1
Application #
8742759
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Prograis, Lawrence J
Project Start
2003-01-01
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
11
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030
Huq, Redwan; Samuel, Errol L G; Sikkema, William K A et al. (2016) Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation. Sci Rep 6:33808
Bian, Fang; Wang, Changjun; Tukler-Henriksson, Johanna et al. (2016) MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions. J Cell Physiol 231:2506-16
de Paiva, Cintia S; Jones, Dan B; Stern, Michael E et al. (2016) Altered Mucosal Microbiome Diversity and Disease Severity in Sjögren Syndrome. Sci Rep 6:23561
Pethő, Zoltán; Tanner, Mark R; Tajhya, Rajeev B et al. (2016) Different expression of β subunits of the KCa1.1 channel by invasive and non-invasive human fibroblast-like synoviocytes. Arthritis Res Ther 18:103
Fortune, Ryan D; Grill, Raymond J; Beeton, Christine et al. (2016) Changes in Gene Expression and Metabolism in the Testes of the Rat following Spinal Cord Injury. J Neurotrauma :
Tajhya, Rajeev B; Hu, Xueyou; Tanner, Mark R et al. (2016) Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts. Cell Death Dis 7:e2426
Pedroza, Mesias; Le, Thuy T; Lewis, Katherine et al. (2016) STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J 30:129-40
Bian, Fang; Pelegrino, Flavia S A; Henriksson, Johanna Tukler et al. (2016) Differential Effects of Dexamethasone and Doxycycline on Inflammation and MMP Production in Murine Alkali-Burned Corneas Associated with Dry Eye. Ocul Surf 14:242-54
Bian, Fang; Shin, Crystal S; Wang, Changjun et al. (2016) Dexamethasone Drug Eluting Nanowafers Control Inflammation in Alkali-Burned Corneas Associated With Dry Eye. Invest Ophthalmol Vis Sci 57:3222-30
Laragione, Teresina; Cheng, Kai F; Tanner, Mark R et al. (2015) The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion. Clin Immunol 158:183-92

Showing the most recent 10 out of 27 publications